Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1600rxa
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS 3	Feb 06	Engineering Information Encompass files have new names
NEWS 4	Feb 16	TOXLINE no longer being updated
NEWS 5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS 6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7	May 07	DGENE Reload
NEWS 8	Jun 20	Published patent applications (A1) are now in USPATFULL
NEWS 9	JUL 13	New SDI alert frequency now available in Derwent's DWPI and DPCI
NEWS 10	Aug 23	In-process records and more frequent updates now in MEDLINE
NEWS 11	Aug 23	PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
NEWS 12	Aug 23	Adis Newsletters (ADISNEWS) now available on STN
NEWS 13	Sep 17	IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS 14	Oct 09	Korean abstracts now included in Derwent World Patents Index
NEWS 15	Oct 09	Number of Derwent World Patents Index updates increased
NEWS 16	Oct 15	Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS 17	Oct 22	Over 1 million reactions added to CASREACT
NEWS 18	Oct 22	DGENE GETSIM has been improved
NEWS 19	Oct 29	AAASD no longer available
NEWS 20	Nov 19	New Search Capabilities USPATFULL and USPAT2
NEWS 21	Nov 19	TOXCENTER(SM) - new toxicology file now available on STN
NEWS 22	Nov 29	COPPERLIT now available on STN
NEWS 23	Nov 29	DWPI revisions to NTIS and US Provisional Numbers
NEWS 24	Nov 30	Files VETU and VETB to have open access
NEWS 25	Dec 10	WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
NEWS 26	Dec 10	DGENE BLAST Homology Search

NEWS EXPRESS	August 15 CURRENT WINDOWS VERSION IS V6.0c, CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP), AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

Examiner Anderson 703-605-1157

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:46:07 ON 17 DEC 2001

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 07:46:15 ON 17 DEC 2001

STRUCTURE FILE UPDATES: 16 DEC 2001 HIGHEST RN 375793-75-2
DICTIONARY FILE UPDATES: 16 DEC 2001 HIGHEST RN 375793-75-2

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09988042.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 07:46:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 0 ANSWERS

Examiner Anderson 703-605-1157

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1 TO 80
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 07:46:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=>
Uploading 09988042.str

L4 STRUCTURE UPLOADED

=> d
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 07:47:40 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 17 TO ITERATE

100.0% PROCESSED 17 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 93 TO 587
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s l4 full
FULL SEARCH INITIATED 07:47:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 411 TO ITERATE

100.0% PROCESSED 411 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

Examiner Anderson 703-605-1157

```
L6            0 SEA SSS FUL L4

=>
Uploading 09988042.str

L7      STRUCTURE UPLOADED

=> s l7
SAMPLE SEARCH INITIATED 07:48:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     49 TO ITERATE

100.0% PROCESSED      49 ITERATIONS                          0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          561 TO     1399
PROJECTED ANSWERS:               0 TO        0

L8            0 SEA SSS SAM L7

=> s l7 full
FULL SEARCH INITIATED 07:48:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    893 TO ITERATE

100.0% PROCESSED     893 ITERATIONS                      1 ANSWERS
SEARCH TIME: 00.00.02

L9            1 SEA SSS FUL L7

=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             400.99     401.14

FILE 'CAPLUS' ENTERED AT 07:48:26 ON 17 DEC 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 17 Dec 2001  VOL 135 ISS 26
FILE LAST UPDATED: 16 Dec 2001  (20011216/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

  This file supports REGlstRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

CAplus now provides online access to patents and literature covered
in CA from 1947 to the present.  On April 22, 2001, bibliographic
```

information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

=> s l9
L10 1 L9

=> d ibib abs hitstr

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1990:77008 CAPLUS
DOCUMENT NUMBER: 112:77008
TITLE: Cycloadditions to the double bonds of methyl (R)-2-tert-butyl-.DELTA.4-1,3-oxazolin-3-carboxylates
AUTHOR(S): Seebach, D.; Stucky, G.; Pfammatter, E.
CORPORATE SOURCE: Inst. Org. Chem., Eidg. Tech. Hochsch., Zurich, CH-8092, Switz.
SOURCE: Chem. Ber. (1989), 122(12), 2377-89
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 112:77008
GI



I

AB The title compds. I (R = H, Me, CH:CH2) reacted with peracids, cyclopropanation reagents, (NC)2C=C(CN)2, OsO4 and dienophiles. The double bond of the oxazolines react in a highly diastereoselective manner, with the attack preferred from the face of the five-membered ring remote from the tert-Bu group. Some of the products obtained undergo or are subjected to further reactions. Stereochem. and synthetic aspects of the reactions are discussed.

IT **122877-23-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 122877-23-0 CAPLUS

CN 7H-Pyrano[3,2-d]oxazole-1(2H)-carboxylic acid, 5-cyano-2-(1,1-dimethylethyl)-3a,7a-dihydro-3a-methyl-7-phenyl-, methyl ester (9CI) (CA INDEX NAME)



=>
Uploading 09988042.str

L11 STRUCTURE UPLOADED

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.17	406.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.59	-0.59

FILE 'REGISTRY' ENTERED AT 07:50:13 ON 17 DEC 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 16 DEC 2001 HIGHEST RN 375793-75-2
DICTIONARY FILE UPDATES: 16 DEC 2001 HIGHEST RN 375793-75-2

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d
L11 HAS NO ANSWERS
L11 STR



Examiner Anderson 703-605-1157

Structure attributes must be viewed using STN Express query preparation.

```
=> s l11
SAMPLE SEARCH INITIATED 07:50:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      1 TO ITERATE

100.0% PROCESSED       1 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            1 TO       80
PROJECTED ANSWERS:               0 TO        0

L12           0 SEA SSS SAM L11

=> s l11 full
FULL SEARCH INITIATED 07:50:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      5 TO ITERATE

100.0% PROCESSED       5 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

L13           0 SEA SSS FUL L11

=>
Uploading 09988042.str

L14     STRUCTURE UPLOADED

=> d
L14 HAS NO ANSWERS
L14             STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l14
SAMPLE SEARCH INITIATED 07:51:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     17 TO ITERATE

100.0% PROCESSED      17 ITERATIONS                              6 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           93 TO      587
PROJECTED ANSWERS:               6 TO      266
```

L15 6 SEA SSS SAM L14

=> s l14 full
FULL SEARCH INITIATED 07:51:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 411 TO ITERATE

100.0% PROCESSED 411 ITERATIONS 179 ANSWERS
SEARCH TIME: 00.00.01

L16 179 SEA SSS FUL L14

=> d scan

L16 179 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-ethyldihydro-5-methyl-5-[4-(phenylsulfonyl)phenyl]-, (3a.alpha.,5.beta.,7a.alpha.)- (9CI)
MF C21 H21 N O6 S

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L16 179 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(benzoyloxy)-5-[(benzoyloxy)methyl]-1-(2-chloro-3-methyl-1-oxopentyl)tetrahydro-, [3aR-[1(2R*,3R*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI)
MF C34 H32 Cl N O10

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L16 179 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-(5-methyl-1-oxo-3-phenylhexyl)-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester (9CI)
MF C35 H51 N O10



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L16 179 ANSWERS REGISTRY COPYRIGHT 2001 ACS
IN Propanoic acid, 2,2-dimethyl-, 1-(2-chloro-1-oxo-3-phenylpentyl)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(2R*,3S*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI)
MF C33 H46 Cl N O10

Absolute stereochemistry.

Examiner Anderson 703-605-1157



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	267.43	673.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.59

FILE 'CAPLUS' ENTERED AT 07:51:43 ON 17 DEC 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1947 - 17 Dec 2001 VOL 135 ISS 26
FILE LAST UPDATED: 16 Dec 2001 (20011216/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGlstRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic

information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

=> s l16
L17 24 L16

=> d ibib abs hitstr 1-24

L17 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:514924 CAPLUS
DOCUMENT NUMBER: 133:238211
TITLE: Novel IBX-mediated processes for the synthesis of amino sugars and libraries thereof
AUTHOR(S): Nicolaou, K. C.; Baran, Phil S.; Zhong, Yong-Li; Vega, Juan A.
CORPORATE SOURCE: Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
SOURCE: Angew. Chem., Int. Ed. (2000), 39(14), 2525-2529
CODEN: ACIEF5; ISSN: 1433-7851
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:238211
GI



I



II



III

AB The cyclization of N-arylcarbamates, eg. I, onto olefins, eg. II, using O-iodoxybenzoic acid/1-hydroxy-1,2-benziodoxol-3-(1H)-one 1-oxide (IBX) is a synthetic protocol for stereoselective amino sugars, eg. III, for compd. libraries and biol. screening.

IT **293293-97-7P 293294-06-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(IBX cyclization for the synthesis of amino sugar libraries from olefins and arylcarbamates)

RN 293293-97-7 CAPLUS

CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6-(acetyloxy)-5-[(acetyloxy)methyl]tetrahydro-1-(4-methoxyphenyl)-, (3aS,5R,6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 293294-06-1 CAPLUS

CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6-(acetyloxy)-5-[(acetyloxy)methyl]tetrahydro-, (3aR,5R,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **293293-98-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(IBX cyclization for the synthesis of amino sugar libraries from olefins and arylcarbamates)
RN 293293-98-8 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6-(acetyloxy)-5-[(acetyloxy)methyl]tetrahydro-, (3aS,5R,6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 70
REFERENCE(S):
(1) Ahmad, H; Carbohydr Res 1981, V93, P288 CAPLUS
(9) Baer, H; Carbohydr Res 1984, V134, P49 CAPLUS
(11) Brakta, M; J Org Chem 1993, V58, P2992 CAPLUS
(12) Brimacombe, J; Carbohydr Res 1982, V110, P207 CAPLUS
(13) Chatterjee, M; J Am Chem Soc 1996, V118, P1938 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1998:593534 CAPLUS
DOCUMENT NUMBER: 129:313198
TITLE: Degradation of derivatives of N-acetyl-D-glucosamine by Rhodococcus rhodochrous IFO 15564: substrate specificity and its application to the synthesis of allyl .alpha.-N-acetyl-D-glucosaminide
AUTHOR(S): Kuboki, Atsuhito; Komiya, Ryosuke; Sekiguchi, Takahiro; Katsuragi, Kenji; Sugai, Takeshi; Ohta, Hiromichi
CORPORATE SOURCE: Department of Chemistry, Keio University, Yokohama, 223-8522, Japan
SOURCE: Biosci., Biotechnol., Biochem. (1998), 62(8), 1581-1585
CODEN: BBBIEJ; ISSN: 0916-8451
PUBLISHER: Japan Society for Bioscience, Biotechnology, and Agrochemistry
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The substrate specificity was studied for the metabolic degrdn. of N-acetyl-D-glucosamine (GlcNAc) derivs. by Rhodococcus rhodochrous IFO 15564 which possesses N-acetyl-D-glucosamine deacetylase as a key-step enzyme. This microorganism degraded a wide range of substrates with modified N-acyl groups. The metabolizing activity of this strain was low toward substrates substituted at the 1,3,4,6-positions of GlcNAc, and GlcNAc itself was suggested to be metabolized via an open-chain aldehyde form. Based on these results, a simplified procedure for the isolation of allyl .alpha.-N-acetyl-D-glucosaminide from an .alpha.,.beta.-anomeric mixt. was developed by selectively hydrolyzing the .beta.-anomer with Jackbean .beta.-N-acetyl-D-glucosaminidase and subsequently degrading the resulting N-acetyl-D-glucosamine in the reaction mixt. with this microorganism.

IT **7103-39-1**
RL: BPR (Biological process); PRP (Properties); BIOL (Biological study); PROC (Process)
(substrate specificity in the degrdn. of acetylglucosamine derivs. by Rhodococcus rhodochrous IFO 15564 and its application to the synthesis of allyl acetylglucosaminide)

RN 7103-39-1 CAPLUS
CN .alpha.-D-Glucopyranose, 2-(carboxyamino)-2-deoxy-, intramol. 2,1-ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1997:88821 CAPLUS
DOCUMENT NUMBER: 126:199307
TITLE: .beta.-Branched .alpha.-Halo Carboxylic Acid Derivatives via Stereoselective 1,4-Addition of Dialkylaluminum Chlorides to .alpha.,.beta.-Unsaturated N-Acyloxazolidinones
AUTHOR(S): Rueck-Braun, Karola; Stamm, Armin; Engel, Stefan; Kunz, Horst
CORPORATE SOURCE: Institut fuer Organische Chemie, Johannes Gutenberg-Universitaet Mainz, Mainz, D-55099, Germany
SOURCE: J. Org. Chem. (1997), 62(4), 967-975
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The stereoselective synthesis of .beta.-branched .alpha.-halo carboxylic acids contg. two newly formed chiral centers is accomplished by a reaction cascade consisting of the 1,4-addn. of dialkylaluminum chlorides to .alpha.,.beta.-unsatd. N-acyloxazolidinones and subsequent reaction of the intermediate aluminum enolates with N-halosuccinimide. The most efficient stereocontrol in these tandem processes has been achieved with

oxazolidinones derived from glucosamine. Not only aryl-substituted but also purely aliph. .beta.-branched .alpha.-halo carboxylic acids can be stereoselectively synthesized by this method. However, the reactions of .beta.-aryl .alpha.,.beta.-unsatd. N-acyloxazolidinones show the highest diastereoselectivity and give one out of four possible diastereomers in high excess.

IT **149198-98-1**
RL: RCT (Reactant)
(.beta.-branched .alpha.-halo carboxylic acid derivs. via stereoselective 1,4-addn. of dialkylaluminum chlorides to .alpha.,.beta.-unsatd. N-acyloxazolidinones)

RN 149198-98-1 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenyl-2-propenyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(E),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **149198-96-9P 149199-04-2P 187845-09-6P 187845-10-9P 187845-11-0P 187845-13-2P 187845-20-1P 187845-22-3P 187845-23-4P 187845-24-5P 187845-25-6P 187845-26-7P 187845-29-0P 187845-31-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(.beta.-branched .alpha.-halo carboxylic acid derivs. via stereoselective 1,4-addn. of dialkylaluminum chlorides to .alpha.,.beta.-unsatd. N-acyloxazolidinones)

RN 149198-96-9 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-(3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149199-04-2 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenyl-2-propenyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(E),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 187845-09-6 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-2-butenyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(E),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 187845-10-9 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-(2-chloro-1-oxo-3-phenylpentyl)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(2R*,3S*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-11-0 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-(2-chloro-1-oxo-3-phenylpentyl)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(2R*,3R*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-13-2 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-(2-chloro-5-methyl-1-oxo-3-phenylhexyl)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(2R*,3S*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-20-1 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(benzoyloxy)-5-[(benzoyloxy)methyl]tetrahydro-, [3aR-(3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-22-3 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(benzoyloxy)-5-[(benzoyloxy)methyl]-1-(2-chloro-1-oxo-3-phenylpentyl)tetrahydro-, [3aR-(3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-23-4 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(benzoyloxy)-5-[(benzoyloxy)methyl]tetrahydro-1-(1-oxo-2-butenyl)-, [3aR-[1(E),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 187845-24-5 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(benzoyloxy)-5-[(benzoyloxy)methyl]tetrahydro-1-(1-oxo-2-pentenyl)-, [3aR-[1(E),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 187845-25-6 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(benzoyloxy)-5-[(benzoyloxy)methyl]tetrahydro-1-(1-oxo-2-hexenyl)-, [3aR-[1(E),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 187845-26-7 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(benzoyloxy)-5-[(benzoyloxy)methyl]tetrahydro-1-(1-oxo-3-phenyl-2-propenyl)-, [3aR-[1(E),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 187845-29-0 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(benzoyloxy)-5-[(benzoyloxy)methyl]-1-(2-chloro-3-ethyl-1-oxohexyl)tetrahydro-, [3aR-[1(2R*,3S*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-31-4 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(benzoyloxy)-5-[(benzoyloxy)methyl]-1-(2-chloro-3-ethyl-1-oxohexyl)tetrahydro-, [3aR-[1(2R*,3R*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **187845-07-4P 187845-08-5P 187845-12-1P**
187845-14-3P 187845-15-4P 187845-16-5P
187845-17-6P 187845-21-2P 187845-27-8P
187845-28-9P 187845-30-3P 187845-32-5P
187845-33-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(.beta.-branched .alpha.-halo carboxylic acid derivs. via stereoselective 1,4-addn. of dialkylaluminum chlorides to .alpha.,.beta.-unsatd. N-acyloxazolidinones)

RN 187845-07-4 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-(2-chloro-1-oxo-3-phenylpentyl)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-(3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-08-5 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-(2-chloro-1-oxo-3-phenylhexyl)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-(3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-12-1 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-(2-bromo-1-oxo-3-phenylpentyl)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(2R*,3S*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-14-3 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-(2-chloro-3-methyl-1-oxopentyl)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(2R*,3R*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-15-4 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-(2-chloro-3-methyl-1-oxopentyl)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(2R*,3S*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-16-5 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-(2-chloro-3,5-dimethyl-1-oxohexyl)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(2R*,3R*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-17-6 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-(2-chloro-3,5-dimethyl-1-oxohexyl)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(2R*,3S*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-21-2 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylpentyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-27-8 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(benzoyloxy)-5-[(benzoyloxy)methyl]-1-(2-chloro-3-methyl-1-oxopentyl)tetrahydro-, [3aR-[1(2R*,3R*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-28-9 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(benzoyloxy)-5-[(benzoyloxy)methyl]-1-(2-bromo-3-methyl-1-oxopentyl)tetrahydro-, [3aR-[1(2R*,3R*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-30-3 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(benzoyloxy)-5-[(benzoyloxy)methyl]-1-(2-bromo-3-ethyl-1-oxohexyl)tetrahydro-, [3aR-[1(2R*,3S*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-32-5 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(benzoyloxy)-5-[(benzoyloxy)methyl]-1-(2-bromo-3-ethyl-1-oxohexyl)tetrahydro-, [3aR-[1(2R*,3R*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187845-33-6 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(benzoyloxy)-5-[(benzoyloxy)methyl]-1-(2-chloro-1-oxo-3-phenylpentyl)tetrahydro-, [3aR-[1(2R*,3S*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1997:2369 CAPLUS
DOCUMENT NUMBER: 126:31345
TITLE: Preparation of tetrahydropyrano[3,2-d]oxazolones as angiogenesis inhibitors
INVENTOR(S): Billington, David C.; Perron-sierra, Francoise; Atassi, Ghanem; Pierre, Alain; Burbridge, Michael; Guilbaud, Nicolas
PATENT ASSIGNEE(S): Adir Et Compagnie, Fr.; Billington, David C.; Perron-Sierra; Atassi, Ghanem; Pierre, Alain; Burbridge, Michael; Guilbaud, Nicolas
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9633999	A1	19961031	WO 1996-FR629	19960424
W: AU, CA, CN, JP, NO, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2733499	A1	19961031	FR 1995-5051	19950427
FR 2733499	B1	19970530		
CA 2219571	AA	19961031	CA 1996-2219571	19960424
AU 9657664	A1	19961118	AU 1996-57664	19960424
EP 822936	A1	19980211	EP 1996-914240	19960424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1185156	A	19980617	CN 1996-194155	19960424
JP 11504029	T2	19990406	JP 1996-532224	19960424
NO 9704870	A	19971229	NO 1997-4870	19971022

PRIORITY APPLN. INFO.: FR 1995-5051 19950427
WO 1996-FR629 19960424
OTHER SOURCE(S): MARPAT 126:31345
GI



I



II

AB Title compds. [I; R1 = R, NHCOR; R = (di)(alkyl)amino, alkyl, alkoxy, etc.; R2 = H or alkyl; R3 = H, alkyl, alkoxy, aryl, etc.; R4 = H; R5 = H, alkyl, (hetero)aryl, etc.; R6 = H, alkyl, alkoxycarbonyl, etc.; R7 = H, alkyl, (CH2)nO2CR8, etc.; R8 = H, alkyl, aryl(alkyl), etc.; X = H, OH, alkoxy, NH2, etc. and Y = H; XY = CH2, O, NOH, etc.; R4Y, R5Y = bond; n = 1-4] were prepd. Thus, 2-acetylfuran was condensed with 1-heptyne and the product treated with NBS in aq. THF to give 2-(1-heptynyl)-2-methyl-3-oxodihydropyran-6-ol which was cyclocondensed with ClCH2CONCO to give title compd. II (R5 = 1-heptynyl). Data for biol activity of I were given.

IT **184421-59-8P 184421-60-1P 184421-61-2P**
184421-62-3P 184421-63-4P 184421-64-5P
184421-65-6P 184421-66-7P 184421-67-8P
184421-68-9P 184421-69-0P 184421-70-3P
184421-71-4P 184421-72-5P 184421-73-6P
184421-74-7P 184421-75-8P 184421-76-9P
184421-77-0P 184421-78-1P 184421-79-2P
184421-80-5P 184421-81-6P 184421-82-7P
184421-83-8P 184421-84-9P 184421-85-0P
184421-86-1P 184421-87-2P 184421-88-3P
184421-89-4P 184421-90-7P 184421-91-8P
184421-92-9P 184421-93-0P 184421-94-1P
184421-95-2P 184421-96-3P 184421-97-4P
184421-98-5P 184421-99-6P 184422-00-2P
184422-01-3P 184422-02-4P 184422-03-5P
184422-04-6P 184422-05-7P 184653-49-4P
184653-50-7P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tetrahydropyrano[3,2-d]oxazolones as angiogenesis inhibitors)

RN 184421-59-8 CAPLUS

CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)-5-(1-heptynyl)dihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 184421-60-1 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)-5-(1-heptenyl)dihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 184421-61-2 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)dihydro-5-methyl-5-(3-pentyloxiranyl)- (9CI) (CA INDEX NAME)



RN 184421-62-3 CAPLUS
CN Spiro[oxirane-2,6'(3'aH)-[5H]pyrano[3,2-d]oxazol]-2'(1'H)-one, 1'-(chloroacetyl)dihydro-5'-methyl-5'-(3-pentyloxiranyl)-, (3'aR,7'aR)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 184421-63-4 CAPLUS
CN Spiro[oxirane-2,6'(3'aH)-[5H]pyrano[3,2-d]oxazole]-1'(2'H)-carboxamide, N-(chloroacetyl)dihydro-5'-methyl-2'-oxo-5'-(3-pentyloxiranyl)- (9CI) (CA INDEX NAME)



RN 184421-64-5 CAPLUS
CN Spiro[oxirane-2,6'(3'aH)-[5H]pyrano[3,2-d]oxazol]-2'(1'H)-one, dihydro-5'-methyl-1'-(1-oxo-3-phenyl-2-propenyl)-5'-(3-pentyloxiranyl)-, (3'aR,7'aR)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 184421-65-6 CAPLUS
CN Spiro[oxirane-2,6'(3'aH)-[5H]pyrano[3,2-d]oxazol]-2'(1'H)-one, 1'-(chloroacetyl)-5'-(2-chloro-1-hydroxyheptyl)dihydro-5'-methyl- (9CI) (CA INDEX NAME)



RN 184421-66-7 CAPLUS
CN Spiro[oxirane-2,6'(3'aH)-[5H]pyrano[3,2-d]oxazol]-2'(1'H)-one, 1'-(chloroacetyl)-5'-(2-chloro-1-hydroxy-5-phenylpentyl)dihydro-5'-methyl- (9CI) (CA INDEX NAME)



RN 184421-67-8 CAPLUS
CN Spiro[oxirane-2,6'(3'aH)-[5H]pyrano[3,2-d]oxazol]-2'(1'H)-one, 1'-(chloroacetyl)-5'-heptyldihydro-5'-methyl- (9CI) (CA INDEX NAME)



RN 184421-68-9 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)-5-heptyldihydro-, (3a.alpha.,5.alpha.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 184421-69-0 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)dihydro-5-methyl-5-[3-(3-phenylpropyl)oxiranyl]- (9CI) (CA INDEX NAME)



RN 184421-70-3 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-1(2H)-carboxamide, tetrahydro-5-methyl-2,6-dioxo-5-(3-pentyloxiranyl)- (9CI) (CA INDEX NAME)



RN 184421-71-4 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 1-(chloroacetyl)-5-(1-heptenyl)tetrahydro-6-hydroxy-5-methyl- (9CI) (CA INDEX NAME)



RN 184421-72-5 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-1(2H)-carboxamide, N-(chloroacetyl)-5-(1-heptynyl)tetrahydro-6-hydroxy-5-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 184421-73-6 CAPLUS
CN Carbamic acid, (chloroacetyl)-, 1-[[(chloroacetyl)amino]carbonyl]-5-(1-heptynyl)hexahydro-5-methyl-2-oxo-5H-pyrano[3,2-d]oxazol-6-yl ester (9CI) (CA INDEX NAME)



RN 184421-74-7 CAPLUS
CN Spiro[oxirane-2,6'(3'aH)-[5H]pyrano[3,2-d]oxazol]-2'(1'H)-one, 1'-benzoyldihydro-5'-methyl-5'-(3-pentyloxiranyl)- (9CI) (CA INDEX NAME)



RN 184421-75-8 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)dihydro-5-methyl-5-(5-phenyl-1-pentynyl)- (9CI) (CA INDEX NAME)



RN 184421-76-9 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)dihydro-5-methyl-5-(5-phenyl-1-pentenyl)- (9CI) (CA INDEX NAME)



RN 184421-77-0 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)dihydro-5-

methyl-5-(5-phenylpentyl)- (9CI) (CA INDEX NAME)



RN 184421-78-1 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)-5-heptyldihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 184421-79-2 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)dihydro-5-(3-methoxy-1-propynyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 184421-80-5 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)dihydro-5-methyl-5-(5-methyl-1-hexynyl)- (9CI) (CA INDEX NAME)



RN 184421-81-6 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)dihydro-5-(3-methoxypropyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 184421-82-7 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)dihydro-5-methyl-5-(5-methylhexyl)- (9CI) (CA INDEX NAME)



RN 184421-83-8 CAPLUS
CN Spiro[oxirane-2,6'(3'aH)-[5H]pyrano[3,2-d]oxazole]-1'(2'H)-carboxamide, N-(chloroacetyl)-5'-(1-heptynyl)dihydro-5'-methyl-2'-oxo- (9CI) (CA INDEX NAME)



RN 184421-84-9 CAPLUS
CN Spiro[oxirane-2,6'(3'aH)-[5H]pyrano[3,2-d]oxazole]-1'(2'H)-carboxamide, 5'-(1-heptynyl)dihydro-5'-methyl-2'-oxo- (9CI) (CA INDEX NAME)



RN 184421-85-0 CAPLUS
CN Spiro[oxirane-2,6'(3'aH)-[5H]pyrano[3,2-d]oxazol]-2'(1'H)-one, 1'-(chloroacetyl)dihydro-5'-methyl-5'-[3-(3-phenylpropyl)oxiranyl]- (9CI) (CA INDEX NAME)



RN 184421-86-1 CAPLUS
CN Carbamic acid, (chloroacetyl)-, 2-chloro-1-[1'-(chloroacetyl)tetrahydro-5'-methyl-2'-oxospiro[oxirane-2,6'(3'aH)-[5H]pyrano[3,2-d]oxazol]-5'-yl]-5-phenylpentyl ester (9CI) (CA INDEX NAME)



RN 184421-87-2 CAPLUS
CN Carbamic acid, (chloroacetyl)-, 1-[[(chloroacetyl)amino]carbonyl]-5-heptylhexahydro-5-methyl-2-oxo-5H-pyrano[3,2-d]oxazol-6-yl ester (9CI) (CA INDEX NAME)



RN 184421-88-3 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-1(2H)-carboxamide, 6-[(aminocarbonyl)oxy]-N-(chloroacetyl)-5-heptyltetrahydro-5-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 184421-89-4 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-1(2H)-carboxamide, 6-[(aminocarbonyl)oxy]-N-(chloroacetyl)-5-(1-heptynyl)tetrahydro-5-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 184421-90-7 CAPLUS
CN Carbamic acid, (chloroacetyl)-, 1-(aminocarbonyl)-5-(1-heptynyl)hexahydro-5-methyl-2-oxo-5H-pyrano[3,2-d]oxazol-6-yl ester (9CI) (CA INDEX NAME)



RN 184421-91-8 CAPLUS

CN 5H-Pyrano[3,2-d]oxazole-1(2H)-carboxamide, 6-[(aminocarbonyl)oxy]-5-(1-heptynyl)tetrahydro-5-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 184421-92-9 CAPLUS
CN Carbamic acid, (chloroacetyl)-, 1-[[(chloroacetyl)amino]carbonyl]hexahydro-5-methyl-2-oxo-5-(5-phenyl-1-pentynyl)-5H-pyrano[3,2-d]oxazol-6-yl ester (9CI) (CA INDEX NAME)



RN 184421-93-0 CAPLUS
CN Carbamic acid, (chloroacetyl)-, 1-[[(chloroacetyl)amino]carbonyl]hexahydro-5-methyl-2-oxo-5-(5-phenylpentyl)-5H-pyrano[3,2-d]oxazol-6-yl ester (9CI) (CA INDEX NAME)



RN 184421-94-1 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-1(2H)-carboxamide, N-(chloroacetyl)-5-(1-heptynyl)tetrahydro-5-methyl-2,6-dioxo- (9CI) (CA INDEX NAME)



RN 184421-95-2 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-1(2H)-carboxamide, N-(chloroacetyl)tetrahydro-5-methyl-5-(5-methyl-1-hexynyl)-2,6-dioxo- (9CI) (CA INDEX NAME)



RN 184421-96-3 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-1(2H)-carboxamide, N-(chloroacetyl)tetrahydro-5-methyl-5-(5-methylhexyl)-2,6-dioxo- (9CI) (CA INDEX NAME)



RN 184421-97-4 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-1(2H)-carboxamide, tetrahydro-5-methyl-5-(5-methylhexyl)-2,6-dioxo- (9CI) (CA INDEX NAME)



RN 184421-98-5 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-1(2H)-carboxamide, N-(chloroacetyl)-5-

heptyltetrahydro-5-methyl-2,6-dioxo- (9CI) (CA INDEX NAME)



RN 184421-99-6 CAPLUS
CN Acetamide, N-[1-(chloroacetyl)-5-heptylhexahydro-5-methyl-2-oxo-5H-pyrano[3,2-d]oxazol-6-yl]- (9CI) (CA INDEX NAME)



RN 184422-00-2 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)dihydro- (9CI) (CA INDEX NAME)



RN 184422-01-3 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)-5-heptyldihydro-5-methyl-, 6-(O-acetyloxime) (9CI) (CA INDEX NAME)



RN 184422-02-4 CAPLUS

CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)-5-heptyldihydro-5-methyl-, 6-oxime (9CI) (CA INDEX NAME)



RN 184422-03-5 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6-butyl-1-(chloroacetyl)-5-heptyltetrahydro-6-hydroxy-5-methyl- (9CI) (CA INDEX NAME)



RN 184422-04-6 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)-5-hexyldihydro-, (3a.alpha.,5.alpha.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 184422-05-7 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)dihydro-5-[(triphenylmethoxy)methyl]-, [3aS-(3a.alpha.,5.beta.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184653-49-4 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)-5-heptyldihydro-, (3a.alpha.,5.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 184653-50-7 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-(chloroacetyl)-5-hexyldihydro-, (3a.alpha.,5.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **184422-08-0P 184422-09-1P 184422-10-4P**
184422-11-5P 184422-12-6P 184422-13-7P
184422-14-8P 184422-15-9P 184422-16-0P
184422-17-1P 184653-51-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of tetrahydropyrano[3,2-d]oxazolones as angiogenesis inhibitors)
RN 184422-08-0 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 5-(1-heptynyl)dihydro-5-methyl-, (3a.alpha.,5.alpha.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 184422-09-1 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 5-(1-heptynyl)tetrahydro-5-methyl-6-methylene- (9CI) (CA INDEX NAME)



RN 184422-10-4 CAPLUS
CN Spiro[oxirane-2,6'(3'aH)-[5H]pyrano[3,2-d]oxazol]-2'(1'H)-one, 5'-(1-heptynyl)dihydro-5'-methyl- (9CI) (CA INDEX NAME)



RN 184422-11-5 CAPLUS
CN Spiro[oxirane-2,6'(3'aH)-[5H]pyrano[3,2-d]oxazol]-2'(1'H)-one, 5'-(1-heptenyl)dihydro-5'-methyl- (9CI) (CA INDEX NAME)



RN 184422-12-6 CAPLUS
CN Spiro[oxirane-2,6'(3'aH)-[5H]pyrano[3,2-d]oxazol]-2'(1'H)-one, dihydro-5'-methyl-5'-(3-pentyloxiranyl)- (9CI) (CA INDEX NAME)



RN 184422-13-7 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 5-heptyldihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 184422-14-8 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 5-(1-heptenyl)dihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 184422-15-9 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 5-(1-heptenyl)tetrahydro-6-hydroxy-5-methyl- (9CI) (CA INDEX NAME)



RN 184422-16-0 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 5-(1-heptynyl)dihydro-5-methyl-, 6-oxime (9CI) (CA INDEX NAME)



RN 184422-17-1 CAPLUS

CN Acetamide, N-(5-heptyl-1,2,3a,7a-tetrahydro-5-methyl-2-oxo-5H-pyrano[3,2-d]oxazol-6-yl)- (9CI) (CA INDEX NAME)



RN 184653-51-8 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 5-(1-heptynyl)dihydro-5-methyl-, (3a.alpha.,5.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L17 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1995:881298 CAPLUS
DOCUMENT NUMBER: 123:286523
TITLE: Preparation of 21-monosaccharide substituted steroid compounds as antiinflammatory agents
INVENTOR(S): Sugai, Kei; Goto, Motoaki; Yoshida, Satoshi; Okuno, Yumiko; Ishii, Takayuki; Kibushi, Nobuyuki; Nishikawa, Hutoshi
PATENT ASSIGNEE(S): Mect Corp., Japan
SOURCE: PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9509177	A1	19950406	WO 1994-JP1602	19940928
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2172983	AA	19950406	CA 1994-2172983	19940928
EP 721956	A1	19960717	EP 1994-927793	19940928
EP 721956	B1	20000802		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 195127	E	20000815	AT 1994-927793	19940928
US 5945404	A	19990831	US 1997-927399	19970910

PRIORITY APPLN. INFO.: JP 1993-243123 A 19930929
WO 1994-JP1602 W 19940928

GI



AB A steroid glycoside (wherein the 21-position of the steroid is substituted by a monosaccharide or an acylated sugar selected from glucose, galactose, mannose, rhamnose, fucose, N-acetylglucosamine, N-acetylgalactosamine, galacturonic acid, glucuronic acid and sialic acid) is prepd. The hydroxy groups of the acylated sugar are protected by toluoyl, benzoyl, p-chlorobenzoyl, or arylalkyl. The preferred steroid is difluprednate, diflorasone, diflucortolone, dexamethasone, betamethasone, or betamethasone valerate. This glycoside shows reduced side effects since it is resistant to common glycosidase and is converted into active steroid by glycosidase increased at inflammation sites. Thus, 300 mg dexamethasone was glycosidated with 1.10 g per(p-toluoyl)-.alpha.-D-glucopyranosyl bromide in the presence of silver triflate and mol. sieve 5A in THF at room temp. for 2 h to give, after silica gel chromatog. and reversed phase HPLC, 32.3% .beta.-D-glucopyranosyldexamethasone (I; R = .beta.-Q, R1 = toluoyl) and 6.7% .alpha.-anomer I (R = .alpha.-Q, R1 = toluoyl), which were treated with NaOMe in MeOH at room temp. for 5 h to give, after HPLC purifn., .beta.-glycoside I (R = .beta.-Q, R1 = H) (II) and .alpha.-glycoside (R = .alpha.-Q, R1 = H) in 88.5 and 40.0%, resp. In paper disk assay, II in vivo decreased granuloma in rats by 47.4% compared to the control. .beta.-D-Glucopyranosyldifluprednate I (R = .beta.-Q1, R1 = H) at 1.0 mg inhibited the croton oil-induced granuloma in rats by 76.4.+-.4.3%. A vaseline-based ointment (0.1% equiv. dexamethasone, 20 mg) contg. acetylated .beta.-D-glucopyranosyldexamethasone I (R = .beta.-Q, R1 = Ac), which was applied to the right ear of mice, inhibited the croton oil-induced ear edema by 49.8.+-.9.7%.

IT **169453-61-6P 169453-62-7P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of monosaccharide-substituted steroid compds. as antiinflammatory agents)

RN 169453-61-6 CAPLUS

CN Pregna-1,4-diene-3,20-dione, 21-[[6,7-bis(acetyloxy)-5-[(acetyloxy)methyl]hexahydro-2-methyl-5H-pyrano[3,2-d]oxazol-2-yl]oxy]-9-fluoro-11,17-dihydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)



RN 169453-62-7 CAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-21-[[hexahydro-6,7-dihydroxy-5-(hydroxymethyl)-2-methyl-5H-pyrano[3,2-d]oxazol-2-yl]oxy]-11,17-dihydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)



L17 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:548863 CAPLUS

DOCUMENT NUMBER: 123:198153

TITLE: Electron impact ionization mass spectra of 6-carbamoyloxy-3-oxo-3,6-dihydro-2H-pyran and 5H-pyrano[3,2-d]oxazole-2,6-dione derivatives

AUTHOR(S): Couladouros, Elias A.; Haroutounian, Serkos A.

CORPORATE SOURCE: Chemistry Laboratory, Agricultural University of Athens, Athens, 11855, Greece

SOURCE: J. Heterocycl. Chem. (1995), 32(2), 579-84
CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB 6-Carbamoyloxy-3-oxo-3,6-dihydro-2H-pyrans and 5H-pyrano[3,2-d]oxazole-2,6-dione derivs., e.g. I, were prepd. their electron impact ionization mass spectra studied. They show a weak mol. ion peak and a base peak of m/z 84 resulting from a retro Diels-Alder fragmentation. The bicyclic system 5H-pyrano[3,2-d]oxazole-2,6-dione gives a characteristic fragmentation pattern with a very stable fragment of oxazolenone.

IT **133150-05-7 145371-52-4 145371-64-8 167968-93-6**
RL: PRP (Properties)
(electron impact ionization mass spectra of (carbamoyloxy)oxodihydropyran and pyranooxazoledione derivs.)

RN 133150-05-7 CAPLUS

CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, tetrahydro-6-hydroxy-1,5-dimethyl-5-[4-(phenylthio)phenyl]-, (3a.alpha.,5.beta.,6.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 145371-52-4 CAPLUS

CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-ethyldihydro-5-methyl-5-[4-(phenylthio)phenyl]-, (3a.alpha.,5.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 145371-64-8 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 1-ethyltetrahydro-6-hydroxy-5-methyl-5-[4-(phenylthio)phenyl]-, (3a.alpha.,5.beta.,6.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 167968-93-6 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, dihydro-1,5-dimethyl-5-[4-(phenylsulfinyl)phenyl]-, (3a.alpha.,5.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **133150-03-5**
RL: PRP (Properties); RCT (Reactant)
(electron impact ionization mass spectra of (carbamoyloxy)oxodihydropyran and pyranooxazoledione derivs.)
RN 133150-03-5 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, dihydro-1,5-dimethyl-5-[4-(phenylthio)phenyl]-, (3a.alpha.,5.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **167968-95-8P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(electron impact ionization mass spectra of (carbamoyloxy)oxodihydropyran and pyranooxazoledione derivs.)
RN 167968-95-8 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-ethyldihydro-5-methyl-5-[4-(phenylsulfonyl)phenyl]-, (3a.alpha.,5.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **133268-29-8P 167968-94-7P 167968-96-9P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(electron impact ionization mass spectra of (carbamoyloxy)oxodihydropyran and pyranooxazoledione derivs.)
RN 133268-29-8 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, dihydro-1,5-dimethyl-5-[4-(phenylsulfonyl)phenyl]-, (3a.alpha.,5.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 167968-94-7 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-ethyldihydro-5-methyl-5-[4-(phenylsulfinyl)phenyl]-, (3a.alpha.,5.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 167968-96-9 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, tetrahydro-6-hydroxy-5-(4-methoxyphenyl)-1,5-dimethyl-, (3a.alpha.,5.beta.,6.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L17 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1995:297127 CAPLUS
DOCUMENT NUMBER: 122:133039
TITLE: Photochemistry of acyl azides. VIII. Do acylnitrenes react as 1,3-dipoles?

Examiner Anderson 703-605-1157

AUTHOR(S): Buck, Karin; Jacobi, Dirk; Ploegert, Yvette; Abraham, Werner
CORPORATE SOURCE: Inst. Chem., Humboldt-Univ., Berlin, Germany
SOURCE: J. Prakt. Chem./Chem.-Ztg. (1994), 336(8), 678-85
CODEN: JPCCEM; ISSN: 0941-1216
DOCUMENT TYPE: Journal
LANGUAGE: German

AB The formation of three- or five-membered heterocyclic rings by the reaction of acylnitrenes with olefins depends on the electron d. at the double bond. The generally expected formation of aziridines by a cheletropic reaction was obsd. in photolysis of aroyl azides in the presence of 2,5-dihydrofuran. With enol ethers, however, oxazolines were directly formed. This [3 + 2] cycloaddn. was regiospecific. The cycloaddn. with a cyclic enol ether, 3,4-dihydro-2-methoxy-2H-pyran, was modestly stereoselective owing to steric hindrance. Very small de-values were found with chiral substituents in the acyl azide. The azide decompn. was also achieved by photoinduced electron transfer. The same cycloaddn. products obtained in direct photolysis of the azides were obtained via radical anions of the acyl azides. By using Michler's ketone as electron donor in the triplet state, the formation of isocyanate, which diminishes the yield of cycloadducts, can be avoided.

IT **160890-94-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(photochem. cycloaddn. reaction of acyl azides with olefins)

RN 160890-94-8 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole, 3a,6,7,7a-tetrahydro-2-[[5-methyl-2-(1-methylethyl)cyclohexyl]oxy]-, [1.alpha.(3aS*,7aS*),2.beta.,5.alpha.]-(9CI) (CA INDEX NAME)

Relative stereochemistry.



L17 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1994:218355 CAPLUS
DOCUMENT NUMBER: 120:218355
TITLE: Stereoselective conjugate addition of organoaluminum chlorides to .alpha.,.beta.-unsaturated carboxylic acid derivatives
AUTHOR(S): Rueck, Karola; Kunz, Horst
CORPORATE SOURCE: Inst. Org. Chem., Univ. Mainz, Mainz, D-55099, Germany
SOURCE: Synthesis (1993), (10), 1018-28
CODEN: SYNTBF; ISSN: 0039-7881
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 120:218355
GI



I



II

AB Organoaluminum chlorides R2AlCl (R = Me, Et, Ph) react smoothly with .alpha.,.beta.-unsatd. N-acyloxazolidinones, e.g. I (R1 = Me, Ph, Et, Pr), providing chiral .beta.-branched carboxylic acid derivs., e.g. II. An unexpected contrast between the mode of reaction of dimethylaluminum chloride and that of the higher homologues is obsd. While diethylaluminum chloride and its higher homologues react with the acceptors at low temp. via a polar pathway, dimethylaluminum chloride requires activation by UV-light or radical initiation under otherwise identical conditions. With bicyclic oxazolidinones derived from galactosamine a high stereoselection is accomplished in the formation of the branched carboxylic acid deriv.

IT **142061-31-2P 149128-39-2P 149198-98-1P 149198-99-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(intermediate in prepn. of bicyclic oxazolidinone sugars)

RN 142061-31-2 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-(3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149128-39-2 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 1-[3-(4-chlorophenyl)-1-oxo-2-propenyl]-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(E),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 149198-98-1 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenyl-2-propenyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(E),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 149198-99-2 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-2-butenyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(E),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **142061-34-5P 142061-35-6P 142061-36-7P**
142061-37-8P 142061-38-9P 142061-39-0P
142061-40-3P 142130-65-2P 142130-66-3P
142130-67-4P 142184-87-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 142061-34-5 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylpentyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142061-35-6 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylbutyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142061-36-7 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylhexyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142061-37-8 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-(5-methyl-1-oxo-3-phenylhexyl)-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142061-38-9 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-(3-methyl-1-oxopentyl)-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142061-39-0 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-(3-methyl-1-oxohexyl)-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142061-40-3 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-(3,5-dimethyl-1-oxohexyl)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142130-65-2 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-(3-methyl-1-oxopentyl)-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(S*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142130-66-3 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-(3-methyl-1-oxohexyl)-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(S*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142130-67-4 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-(3,5-dimethyl-1-oxohexyl)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(S*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142184-87-0 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylbutyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(S*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1993:603754 CAPLUS
DOCUMENT NUMBER: 119:203754
TITLE: Preparation of galactosamine analogs
INVENTOR(S): Kunz, Horst; Rueck, Karola
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 11 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

DE 4113327	A1	19921029	DE 1991-4113327	19910424

OTHER SOURCE(S): MARPAT 119:203754

GI



I II

AB The title compds. [I; II; R = alkyl, alkenyl] are prepd. E.g., 3,4,6-tri-O-acetyl-D-galactal in MeOH was treated with NaOMe-MeOH and then pivaloyl chloride to give 3,4,6-tri-O-pivaloyl-D-galactal, which was treated with NaN3 in MeCN contg. Ce(NH4)2(NO3)6 to give 2-azido-3,4,6-tri-O-pivaloyl-2-deoxy-.alpha.,.beta.-D-galactopyranosyl nitrate, which was heated with NaNO2 in dioxane-H2O at 80.degree. to give 3,4,6-tri-O-pivaloyl-2-azido-2-deoxy-D-galactopyranose, which was reacted with CO2 in dioxane contg. PPh3 to give I.

IT **142061-31-2 149128-39-2 149128-40-5 149128-41-6 149198-96-9 149198-98-1 149198-99-2**
RL: RCT (Reactant)
(in prepn. of galactosamine analogs)

RN 142061-31-2 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-(3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149128-39-2 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 1-[3-(4-chlorophenyl)-1-oxo-2-propenyl]-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(E),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 149128-40-5 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(acetyloxy)-5-[(acetyloxy)methyl]tetrahydro-1-(1-oxo-3-phenylpentyl)- (9CI) (CA INDEX NAME)



RN 149128-41-6 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-[(3-methylbicyclo[2.2.1]hept-5-en-2-yl)carbonyl]-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(1R*,2R*,3S*,4S*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149198-96-9 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-(3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149198-98-1 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenyl-2-propenyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(E),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 149198-99-2 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-2-butenyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(E),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **149128-49-4P 149199-01-9P 149199-02-0P 149199-03-1P 149199-04-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 149128-49-4 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3,4-diphenylbutyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149199-01-9 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylpentyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(S*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149199-02-0 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylbutyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(S*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149199-03-1 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylbutyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149199-04-2 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenyl-2-propenyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(E),3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **142061-38-9P 142130-65-2P 149128-34-7P**
149198-90-3P 149198-91-4P 149198-92-5P
149198-93-6P 149198-94-7P 149198-95-8P
149199-00-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, by alkylation of N-acyloxazolidine derivs.)

RN 142061-38-9 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-(3-methyl-1-oxopentyl)-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142130-65-2 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-(3-methyl-1-oxopentyl)-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(S*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149128-34-7 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-[3-(4-chlorophenyl)-1-oxopentyl]-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149198-90-3 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylpentyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester (9CI) (CA INDEX NAME)



RN 149198-91-4 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylbutyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester (9CI) (CA INDEX NAME)



RN 149198-92-5 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-(5-methyl-1-oxo-3-phenylhexyl)-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester (9CI) (CA INDEX NAME)



RN 149198-93-6 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylhexyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester (9CI) (CA INDEX NAME)



RN 149198-94-7 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-(3,5-dimethyl-1-oxohexyl)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester (9CI) (CA INDEX NAME)



RN 149198-95-8 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-(3-methyl-1-oxohexyl)-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester (9CI) (CA INDEX NAME)



RN 149199-00-8 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-[3-(4-chlorophenyl)-1-oxopentyl]-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(S*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1993:59622 CAPLUS
DOCUMENT NUMBER: 118:59622
TITLE: Synthesis and antimicrobial properties of 2H-pyran-3(6H)-one derivatives and related compounds
AUTHOR(S): Georgiadis, Minas P.; Couladouros, Elias A.; Delitheos, Andreas K.
CORPORATE SOURCE: Chem. Lab., Agric. Univ. Athens, Athens, 118 55, Greece
SOURCE: J. Pharm. Sci. (1992), 81(11), 1126-31
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II



III

AB The synthesis of several derivs. of 2H-pyran-3(6H)-ones and their Michael adducts is described. Thus, 4-BrC6H4COMe underwent reaction with furan and oxidative rearrangement to give hydroxypyranone I. Phenylthio, benzenesulfonyl, p-acetylaminobenzenesulfonyl, and p-bromophenyl substituents are beneficial for activity against gram-pos. bacteria. [(Phenylthio)phenyl]methylpyranone II (R = H, R1 = OMe, n = 0) showed a

min. inhibitory concn. of 1.56 .mu.g/mL against Staphylococcus aureus ATCC 2593, and II (R = OCOC6H4NO2-4, R1 = H, n = 2) showed a min. inhibitory concn. of 0.75 .mu.g/mL against Streptococcus sp. C203M. In general, derivs. of 6-hydroxy-2H-pyran-3(6H)-ones with substituents at C-2 and C-6 showed significant activity against gram-pos. bacteria. More specifically, the bulkier the C-2 substituent, the greater the antibacterial activity. Michael adducts of thiols, e.g., (aminobenzenethio)(bromophenyl)pyranone III, showed activity, which may be due to a retro-Michael reaction. In conclusion, the .alpha.,.beta.-enone system is essential for the activity of 6-hydroxy-2H-pyran-3(6H)-ones, and the size and nature of substituents at C-2 are assocd. with antimicrobial activity.

IT **145415-59-4**
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(bactericidal activity of)

RN 145415-59-4 CAPLUS

IT **133150-03-5P 145371-64-8P 145371-66-0P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and bactericidal activity of)

RN 133150-03-5 CAPLUS

CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, dihydro-1,5-dimethyl-5-[4-(phenylthio)phenyl]-, (3a.alpha.,5.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 145371-64-8 CAPLUS

CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 1-ethyltetrahydro-6-hydroxy-5-methyl-5-[4-(phenylthio)phenyl]-, (3a.alpha.,5.beta.,6.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 145371-66-0 CAPLUS
CN Acetamide, N-[1-ethylhexahydro-5-methyl-2-oxo-5-[4-(phenylthio)phenyl]-5H-pyrano[3,2-d]oxazol-6-yl]-, (3a.alpha.,5.beta.,6.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **145371-65-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn., acetylation, and bactericidal activity of)
RN 145371-65-9 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-ethyldihydro-5-methyl-5-[4-(phenylthio)phenyl]-, 6-oxime, (3a.alpha.,5.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)



IT **145371-52-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., bactericidal activity, and condensation of, with hydroxylamine)
RN 145371-52-4 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, 1-ethyldihydro-5-methyl-5-[4-(phenylthio)phenyl]-, (3a.alpha.,5.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L17 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1992:592210 CAPLUS
DOCUMENT NUMBER: 117:192210
TITLE: Syntheses of N-acyl and N-alkoxycarbonyl derivatives of 2-[(alkoxycarbonyl)amino]-2-deoxy-D-glucose.
AUTHOR(S): Lafont, Dominique; Boullanger, Paul
CORPORATE SOURCE: ESCIL, Univ. Lyon I, Villeurbanne, 69622, Fr.
SOURCE: J. Carbohydr. Chem. (1992), 11(5), 567-86
CODEN: JCACDM; ISSN: 0732-8303
DOCUMENT TYPE: Journal
LANGUAGE: English

AB N-Acyl and N-alkoxycarbonyl derivs. of 1,3,4,6-tetra-O-acetyl-2-alkoxycarbonylamino-2-deoxy-.beta.-D-glucopyranose were synthesized using mixed anhydrides and sym. or unsym. pyrocarbonates. These derivs. were used as donors in 1,2-trans-glycosylation reactions promoted by Lewis acids. Besides the expected .beta.-D-glycosides, cyclization and rearrangement side-products were often encountered in such glycosylations.

IT **76548-23-7**
RL: RCT (Reactant)
(allyloxycarbonylation of, with allyl chloroformate)

RN 76548-23-7 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(acetyloxy)-5-[(acetyloxy)methyl]tetrahydro-, [3aR-(3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **143880-97-1P 143881-01-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 143880-97-1 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-1(2H)-carboxylic acid, 6,7-bis(acetyloxy)-5-[(acetyloxy)methyl]tetrahydro-2-oxo-, 2-propenyl ester, [3aR-(3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143881-01-0 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(acetyloxy)-5-[(acetyloxy)methyl]-1-benzoyltetrahydro-, [3aR-(3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1992:571856 CAPLUS
DOCUMENT NUMBER: 117:171856
TITLE: Ferric chloride, an anomerization catalyst for the preparation of alkyl .alpha.-glycopyranosides
AUTHOR(S): Ikemoto, Norihiro; Kim, Oak Kyung; Lo, Lee Chiang; Satyanarayana, Vunnam; Chang, Maryland; Nakanishi, Koji
CORPORATE SOURCE: Dep. Chem., Columbia Univ., New York, NY, 10027, USA
SOURCE: Tetrahedron Lett. (1992), 33(30), 4295-8
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 117:171856
AB Anhyd. FeCl3 in CH2Cl2 has been found to readily anomerize .beta.-glycopyranosides to their corresponding .alpha.-anomers in good yields and selectivities at room temp. Acetyl- and benzoyl-protected oxygen sugars yielded the best results.
IT **143723-22-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 143723-22-2 CAPLUS
CN Benzoic acid, 4-bromo-, 5-[[(4-bromobenzoyl)oxy]methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-(3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Examiner Anderson 703-605-1157



L17 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1992:449102 CAPLUS
DOCUMENT NUMBER: 117:49102
TITLE: Selective protections on 2-allyloxycarbonylamino-1,6-anhydro-2-deoxy-.beta.-D-glucopyranose
AUTHOR(S): Bouali, Abderrahime; Boullanger, Paul; Lafont, Dominique; Fenet, Bernard
CORPORATE SOURCE: ESCIL, Univ. Claude Bernard Lyon I, Villeurbanne, F-69622, Fr.
SOURCE: Carbohydr. Res. (1992), 228(1), 81-93
CODEN: CRBRAT; ISSN: 0008-6215
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 117:49102
GI



I

AB Regioselective monoacetylation of anhydro-2-deoxy-.beta.-D-glucopyranose I (R = R1 = H) (II) gave a mixt. of 3-O-acetyl and 4-O-acetyl derivs., the structures of which were established by two-dimensional, phase-sensitive NOESY and confirmed by chem. proofs. Benzylation of II, on the other hand, led to I [R = H (III), CH2Ph (IV), R1 = CH2Ph]. The regioselective

cleavage of III with TiCCl4 gave the expected 3-O-benzyl deriv., the structure of which was ascertained by chem. proofs; the same reaction performed on IV led to the opening of the anhydro ring to afford 3-benzyl-[3,4-di-O-benzyl-1,2-dideoxy-.alpha.-D-glucopyrano]-[2,1-d]-2-oxazolidone.

IT **142269-97-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 142269-97-4 CAPLUS

CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, tetrahydro-5-(hydroxymethyl)-6,7-bis(phenylmethoxy)-1-(phenylmethyl)-, [3aR-(3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1992:449098 CAPLUS

DOCUMENT NUMBER: 117:49098

TITLE: A bicyclic carbohydrate oxazolidinone template for stereoselective 1,4-additions of organoaluminum chlorides to unsaturated carboxylic acid derivatives

AUTHOR(S): Rueck, Karola; Kunz, Horst

CORPORATE SOURCE: Inst. Org. Chem., Univ. Mainz, Mainz, D-6500, Germany

SOURCE: Synlett (1992), (4), 343-4
CODEN: SYNLES; ISSN: 0936-5214

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 117:49098

GI



I

AB The radical 1,4-addn. of Me2AlCl and the polar 1,4-addn. of higher dialkylaluminum chlorides to .alpha.,.beta.-unsatd. carboxylic acid derivs., e.g. I (R = Me3CCO, R1 = CH:CHR2, R2 = Me, Ph), are achieved with high stereoselectivity by using a bicyclic carbohydrate oxazolidinone I

(R1 = H) derived from galactosamine as the chiral auxiliary.

IT **142061-31-2**
RL: RCT (Reactant)
(amidation of)

RN 142061-31-2 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-(3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **142061-32-3P 142061-33-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and stereoselective addn. reaction of, with dialkylaluminum chloride)

RN 142061-32-3 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenyl-2-propenyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-(3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



Examiner Anderson 703-605-1157

RN 142061-33-4 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-2-butenyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-(3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT **142061-34-5P 142061-35-6P 142061-36-7P**
142061-37-8P 142061-38-9P 142061-39-0P
142061-40-3P 142130-62-9P 142130-63-0P
142130-64-1P 142130-65-2P 142130-66-3P
142130-67-4P 142184-87-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 142061-34-5 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylpentyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142061-35-6 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylbutyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142061-36-7 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylhexyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142061-37-8 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-(5-methyl-1-oxo-3-phenylhexyl)-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Examiner Anderson 703-605-1157



RN 142061-38-9 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-(3-methyl-1-oxopentyl)-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142061-39-0 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-(3-methyl-1-oxohexyl)-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142061-40-3 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-(3,5-dimethyl-1-oxohexyl)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(R*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142130-62-9 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylpentyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(S*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142130-63-0 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylhexyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(S*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142130-64-1 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-(5-methyl-1-oxo-3-phenylhexyl)-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(S*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142130-65-2 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-(3-methyl-1-oxopentyl)-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(S*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142130-66-3 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-1-(3-methyl-1-oxohexyl)-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(S*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142130-67-4 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 1-(3,5-dimethyl-1-oxohexyl)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(S*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142184-87-0 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 5-[(2,2-dimethyl-1-oxopropoxy)methyl]hexahydro-2-oxo-1-(1-oxo-3-phenylbutyl)-5H-pyrano[3,2-d]oxazole-6,7-diyl ester, [3aR-[1(S*),3a.alpha.,5.alpha.,6.alpha.,7.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1991:185332 CAPLUS
DOCUMENT NUMBER: 114:185332
TITLE: Stereoselective ring closure of 6-{[(methylamino)carbonyl]oxy}-2H-pyran-3(6H)-ones. Formation of the 5H-pyrano[3,2-d]oxazole-2,6-dione
AUTHOR(S): Georgiadis, Minas P.; Couladouros, Elias A.
CORPORATE SOURCE: Chem. Lab., Agric. Univ. Athens, Athens, 11855, Greece
SOURCE: J. Heterocycl. Chem. (1990), 27(6), 1757-60
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:185332
GI



AB The treatment of anomeric mixts. of pyranones [I; R = p-(PhS)C6H4 and p-(PhSO2)C6H4] with MeNCO results in the formation of pyranooxazolediones (II) from the .alpha.-anomers of (I) and methylamino derivs. (III) from the .beta.-anomers of (I). (II) are apparently formed by an intramol. endo-Michael addn. of intermediates (IV). The treatment of (III) with Et3N results in its isomerization and the quant. formation of (II). Thus, (II) can be obtained from (I) in 2 steps with high overall yield. The outcome of the same reaction of (I; R = H) is also examd.

IT **133150-06-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reductive acetylation of)
RN 133150-06-8 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, dihydro-1,5-dimethyl-5-[4-(phenylthio)phenyl]-, 6-oxime, (3a.alpha.,5.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)



IT **133150-05-7P 133150-07-9P 133150-10-4P**
133268-29-8P 133268-30-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 133150-05-7 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, tetrahydro-6-hydroxy-1,5-dimethyl-5-[4-(phenylthio)phenyl]-, (3a.alpha.,5.beta.,6.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 133150-07-9 CAPLUS
CN Acetamide, N-[hexahydro-1,5-dimethyl-2-oxo-5-[4-(phenylthio)phenyl]-5H-pyrano[3,2-d]oxazol-5-yl]-, (3a.alpha.,5.beta.,6.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 133150-10-4 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, dihydro-1,5-dimethyl-, (3a.alpha.,5.alpha.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 133268-29-8 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, dihydro-1,5-dimethyl-5-[4-(phenylsulfonyl)phenyl]-, (3a.alpha.,5.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 133268-30-1 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, dihydro-1,5-dimethyl-, (3a.alpha.,5.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **133150-03-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., redn. and reaction of, with hydroxylamine hydrochloride)
RN 133150-03-5 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, dihydro-1,5-dimethyl-5-[4-(phenylthio)phenyl]-, (3a.alpha.,5.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L17 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1990:612512 CAPLUS
DOCUMENT NUMBER: 113:212512
TITLE: The use of N-alkoxycarbonyl derivatives of 2-amino-2-deoxy-D-glucose as donors in glycosylation reactions
AUTHOR(S): Boullanger, Paul; Jouineau, Martine; Bouammali, Boufelja; Lafont, Dominique; Descotes, Gerard
CORPORATE SOURCE: Lab. Chim. Org. II, Univ. Lyon I, Villeurbanne, F-69622, Fr.
SOURCE: Carbohydr. Res. (1990), 202, 151-64
CODEN: CRBRAT; ISSN: 0008-6215
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 113:212512
AB 1,3,4,6-Tetra-O-acetyl-2-alkoxycarbonylamino-2-deoxy-.beta.-D-glucopyranoses and 3,4,6-tri-O-acetyl-2-alkoxycarbonylamino-2-deoxypyranosyl bromides were used as donors in glycosylation reactions with model alcs. .beta.-Glycosides were obtained in good yields and with a high degree of 1,2-trans stereoselectivity. An oxazolidinone was formed as the main product from the reaction of some of the glucopyranosyl bromides with alcs. of low reactivity, but the formation of all products could be interpreted by a strong participation of the alkoxycarbonylamino group.

IT **76548-23-7P**
RL: FORM (Formation, nonpreparative); PREP (Preparation)
(formation of, during glycosylation by (alkoxycarbonyl)aminodeoxyglucopyranose bromides)
RN 76548-23-7 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(acetyloxy)-5-[(acetyloxy)methyl]tetrahydro-, [3aR-(3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1989:458212 CAPLUS
DOCUMENT NUMBER: 111:58212
TITLE: A novel glycosylation reaction of 2-amino-2-deoxy-D-glucopyranose using dimethylphosphinothioate
AUTHOR(S): Inazu, Toshiyuki; Yamanoi, Takashi
CORPORATE SOURCE: Noguchi Inst., Tokyo, 173, Japan
SOURCE: Chem. Lett. (1989), (1), 69-72
CODEN: CMLTAG; ISSN: 0366-7022
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 111:58212
AB .beta.-Glucosides were stereoselectively obtained in good yields from 3,4,6-tri-O-benzyl-2-benzyloxycarbonylamino-2-deoxy-.alpha.-D-glucopyranosyl dimethylphosphinothioate with several alcs. in the presence of iodine and a catalytic amt. of trityl or perchlorate salts.
IT **121682-66-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 121682-66-4 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, tetrahydro-6,7-bis(phenylmethoxy)-5-[(phenylmethoxy)methyl]-, [3aR-(3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1988:94857 CAPLUS
DOCUMENT NUMBER: 108:94857
TITLE: N-Allyloxycarbonyl derivatives of D-glucosamine as promoters of 1,2-trans-glucosylation in Koenigs-Knorr reactions and in Lewis acid-catalyzed condensations
AUTHOR(S): Boullanger, Paul; Banoub, Joseph; Descotes, Gerard
CORPORATE SOURCE: Ec. Super. Chim. Ind., Univ. Lyon I, Villeubranne, 69622, Fr.
SOURCE: Can. J. Chem. (1987), 65(6), 1343-8
CODEN: CJCHAG; ISSN: 0008-4042
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:94857

AB 3,4,6-Tri-O-acetyl-2-N-allyloxycarbonyl-2-amino-2-deoxy-.alpha.-D-glucopyranosyl bromide and 1,3,4,6-tetra-O-acetyl-2-N-allyloxycarbonyl-2-amino-2-deoxy-.beta.-D-glucopyranose were used in Koenigs-Knorr reactions or Lewis acid-catalyzed glycosidations, resp. Glucosides of simple alcs. and disaccharides were prepd. in good to excellent yields. The N-allyloxycarbonyl protective group was, easy to remove with Pd(0) complexes, affording, after acetylation, the N-acetyl-.beta.-D-glucosamine glucosides under very smooth conditions.

IT **76548-23-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 76548-23-7 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(acetyloxy)-5-[(acetyloxy)methyl]tetrahydro-, [3aR-(3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1982:455639 CAPLUS
DOCUMENT NUMBER: 97:55639
TITLE: Products from furans. 3. Crystal and molecular structure, proton nuclear magnetic resonance, and conformational studies of 2-methyl-2-aryl-substituted 6-hydroxy-2H-pyran-3(6H)-one derivatives
AUTHOR(S): Georgiadis, Minas P.; Couladouros, Elias A.; Polissiou, Moschos G.; Filippakis, S. E.; Mentzafos, D.; Terzis, A.
CORPORATE SOURCE: Chem. Lab., Agric. Univ. Athens, Athens, Greece
SOURCE: J. Org. Chem. (1982), 47(16), 3054-8
CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Treating p-PhSO2C6H4COMe with 2-furyllithium gave furan I, which underwent ring expansion when treated with m-ClC6H4C(O)OOH to give 20% cis- and 80% trans-II (R = H). Treating II (R = H) with MeI give II (R = Me); using MeNCO gave II (R = MeNHCO). Crystal structures showed that the p-PhSO2C6H4 group in trans-II (R = MeNHCO) and cis-II (R = Me) has a pseudo axial orientation relative to the 6-substituent; both II have a sofa configuration. PMR vicinal and allylic coupling consts. of II and related compds. are correlated, and ambiguities in their use for direct configurational assignment are clarified. A new equation of the Karplus-Garbisch type is also given which correlates these coupling consts. with the dihedral angle between the vinyl and allylic H bonds. The conformational equil. of II is discussed.

IT **81830-87-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 81830-87-7 CAPLUS

CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, dihydro-1,5-dimethyl-5-[4-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



L17 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1981:192611 CAPLUS
DOCUMENT NUMBER: 94:192611
TITLE: Structures of the decomposition products of chlorozotocin: new intramolecular carbamates of 2-amino-2-deoxyhexoses
AUTHOR(S): Hammer, Charles F.; Loranger, Richard A.; Schein, Philip S.
CORPORATE SOURCE: Dep. Chem., Georgetown Univ., Washington, DC, 20057, USA

SOURCE: J. Org. Chem. (1981), 46(8), 1521-31
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Six intramol. five-membered-ring carbamate sugars were obtained from the decompn. of chlorozotocin (I) in phosphate and triethylammonium bicarbonate buffers at pH 7.4. Their mol. structures [II, III, IV (R = H, R1 = OH; R = OH, R1 H), V, and VI] were proved by spectroscopic methods and chem. inference. VI may exist as its open chain aldehyde hydrate.

IT **7103-39-1**
RL: RCT (Reactant)
(decompn. product of chlorozotocin)
RN 7103-39-1 CAPLUS
CN .alpha.-D-Glucopyranose, 2-(carboxyamino)-2-deoxy-, intramol. 2,1-ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **76481-07-7P 76548-23-7P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and NMR of)
RN 76481-07-7 CAPLUS
CN .alpha.-D-Glucopyranose, 2-(acetylcarboxyamino)-2-deoxy-, intramol. 2,1-ester, 3,4,6-triacetate (9CI) (CA INDEX NAME)



RN 76548-23-7 CAPLUS
CN 5H-Pyrano[3,2-d]oxazol-2(1H)-one, 6,7-bis(acetyloxy)-5-[(acetyloxy)methyl]tetrahydro-, [3aR-(3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Examiner Anderson 703-605-1157



IT **76481-06-6P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and mass spectrum of)
RN 76481-06-6 CAPLUS
CN .alpha.-D-Glucopyranose, 2-(carboxyamino)-2-deoxy-3,4,6-tris-O-(trimethylsilyl)-, intramol. 2,1-ester (9CI) (CA INDEX NAME)



L17 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1980:514255 CAPLUS
DOCUMENT NUMBER: 93:114255
TITLE: A new 7-ring cycloaddition reaction
AUTHOR(S): Hendrickson, James B.; Farina, James S.
CORPORATE SOURCE: Edison Chem. Lab., Brandeis Univ., Waltham, MA, 02254, USA
SOURCE: J. Org. Chem. (1980), 45(16), 3359-61
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



II



III



IV

AB The pyrolysis of 2-acetoxy-1-oxacyclohex-3-en-5-one (I) in the presence of active dienophiles yields oxygen-bridged cycloheptenone adducts, e.g., II or III. The precursor IV is made from furfuryl alc. by bromination, hydrolysis and acetylation and is presumed to lose HOAc on pyrolysis to

give the active reagent, 3-oxopyrylium, for cycloaddn.

IT **74019-33-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, in synthesis of epoxycycloheptafurans)

RN 74019-33-3 CAPLUS

CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,3aH)-dione, dihydro-1-phenyl- (9CI) (CA INDEX NAME)



L17 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1976:105996 CAPLUS

DOCUMENT NUMBER: 84:105996

TITLE: Preparative and exploratory carbohydrate chemistry. Chemistry of the glycosidic linkage. 2-Alkoxy-3-(p-nitrobenzoyl)-2-phenyl-4,5-[.alpha.-D-glucopyrano]-2-oxazolidines, a new class of carbohydrate 1,2-ortho-acid derivative

AUTHOR(S): Hanessian, Stephen; Cassinelli, Giuseppe; Casey, Michael

CORPORATE SOURCE: Dep. Chem., Univ. Montreal, Montreal, Que., Can.

SOURCE: Carbohydr. Res. (1975), 44(2), C18-C21
CODEN: CRBRAT

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB Treatment of oxazoline I with p-O2NC6H4COCl in CH2Cl2 1-2 days at 25.degree. followed by addn. of pyridine and MeOH 2 hr at 25.degree. gave a mixt. contg. 70% II (R = Me, R1 = Ac) and 20% III (R = Me). Analogously obtained was II (R = Me2CH, R1 = Ac) which underwent acid-catalyzed rearrangement to give 50% III (R = Me2CH). I treated with p-O2NC6H4COCl followed by 1,2:3,4-di-O-isopropylidene-.alpha.-D-galactopyranose gave an oxazolidine deriv. which was rearranged to 67% IV (R = p-O2NC6H4CO) which was hydrolyzed to give IV (R = H).

IT **58510-47-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and hydrolysis of)

RN 58510-47-7 CAPLUS

CN 5H-Pyrano[3,2-d]oxazole-6,7-diol, 5-[(acetyloxy)methyl]hexahydro-2-methoxy-1-(4-nitrobenzoyl)-2-phenyl-, diacetate (ester) (9CI) (CA INDEX NAME)



IT **58510-51-3P 58568-98-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and rearrangement of)
RN 58510-51-3 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-6,7-diol, 5-[(acetyloxy)methyl]hexahydro-2-(1-methylethoxy)-1-(4-nitrobenzoyl)-2-phenyl-, diacetate (ester) (9CI) (CA INDEX NAME)



RN 58568-98-2 CAPLUS
CN .alpha.-D-Galactopyranose, 6-O-[6,7-bis(acetyloxy)-5-[(acetyloxy)methyl]hexahydro-1-(4-nitrobenzoyl)-2-phenyl-5H-pyrano[3,2-d]oxazol-2-yl]-1,2:3,4-bis-O-(1-methylethylidene)-, [2R-(2.alpha.,3a.alpha.,5.alpha.,6.beta.,7.alpha.,7a.alpha.)]- (9CI) (CA INDEX NAME)



IT **58510-49-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., acetylation and solvolysis of)
RN 58510-49-9 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-6,7-diol, hexahydro-5-(hydroxymethyl)-2-methoxy-1-(4-nitrobenzoyl)-2-phenyl- (9CI) (CA INDEX NAME)



L17 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1972:140773 CAPLUS
DOCUMENT NUMBER: 76:140773
TITLE: Fungicidal and amebicidal pyrano[3,2-d]oxazole derivatives
INVENTOR(S): Laliberte, Real
PATENT ASSIGNEE(S): Ayerst, McKenna and Harrison Ltd.
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3631175	A	19711228	US 1970-28540	19700414

GI For diagram(s), see printed CA Issue.

AB Furan was treated with BuLi and RR1CO [BzH, PhCOCH2Cl, 3,4-Me2C6H3COPh, p-PhCH2OC6H4-CHO, PhCH2COPh, PhCH(OH)COPh, Ph2CHCHO, p-PhC6H4-COMe, p-PhC6H4COEt, p-PhC6H4COPr, p-(p-ClC6H4)C6H4CO-Me] to give hydroxypyranones (I) (R2 = H); esterification with R3NCO (R3 = Ph, Me, Et, Pr, Bu, p-ClC6H4) gave carbamates (I, R2 = CONHR3) (II), which with and without isolation were cyclized by refluxing in C6H6 to give III. II had coccidiostatic activity.

IT **36067-37-5P 36067-38-6P 36067-39-7P**
36067-40-0P 36067-41-1P 36067-42-2P
36067-43-3P 36067-44-4P 36067-45-5P
36067-46-6P 36067-47-7P 36067-48-8P
36067-49-9P 36067-50-2P 36067-51-3P
36067-52-4P 36067-53-5P 36275-08-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 36067-37-5 CAPLUS

CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione, dihydro-1,5-diphenyl- (9CI) (CA INDEX NAME)



RN 36067-38-6 CAPLUS

CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione, 5-(chloromethyl)dihydro-1-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 36067-39-7 CAPLUS

CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione, 1-butyl-5-(3,4-dimethylphenyl)dihydro-5-phenyl- (9CI) (CA INDEX NAME)



RN 36067-40-0 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione, 5-(3,4-dimethylphenyl)dihydro-1,5-diphenyl- (9CI) (CA INDEX NAME)



RN 36067-41-1 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione, dihydro-1-methyl-5-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 36067-42-2 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione, dihydro-1,5-diphenyl-5-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 36067-43-3 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione, 5-(diphenylmethyl)dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 36067-44-4 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione, 5-[1,1'-biphenyl]-4-yldihydro-1,5-dimethyl- (9CI) (CA INDEX NAME)



RN 36067-45-5 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione, 5-[1,1'-biphenyl]-4-yl-5-ethyldihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 36067-46-6 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione,, 5-[1,1'-biphenyl]-4-yldihydro-1-methyl-5-propyl- (9CI) (CA INDEX NAME)



RN 36067-47-7 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione, 5-[1,1'-biphenyl]-4-yl-1-ethyldihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 36067-48-8 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione, 5-[1,1'-biphenyl]-4-yldihydro-5-methyl-1-propyl- (9CI) (CA INDEX NAME)



RN 36067-49-9 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione, 5-[1,1'-biphenyl]-4-yl-1-butyldihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 36067-50-2 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione, 5-[1,1'-biphenyl]-4-yldihydro-5-

methyl-1-phenyl- (9CI) (CA INDEX NAME)



RN 36067-51-3 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione, 5-[1,1'-biphenyl]-4-yl-1-(4-chlorophenyl)dihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 36067-52-4 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione, 5-(4'-chloro[1,1'-biphenyl]-4-yl)dihydro-1,5-dimethyl- (9CI) (CA INDEX NAME)



RN 36067-53-5 CAPLUS
CN Spiro[cyclohexane-1,5'-[5H]pyrano[3,2-d]oxazole]-2',6'(1'H,3'aH)-dione, dihydro-1'-phenyl- (9CI) (CA INDEX NAME)



RN 36275-08-8 CAPLUS
CN 5H-Pyrano[3,2-d]oxazole-2,6(1H,7H)-dione, 3a,7a-dihydro-5-(hydroxyphenylmethyl)-1-methyl-5-phenyl- (9CI) (CA INDEX NAME)



L17 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1967:18783 CAPLUS
DOCUMENT NUMBER: 66:18783
TITLE: Structure of the alkaloids fruticosine and fruticosamine and their synthesis from kopsine
AUTHOR(S): Guggisberg, A.; Hesse, Manfred; Von Philipsborn, Wolfgang; Nagarajan, Kuppuswamy; Schmid, Hans
CORPORATE SOURCE: Univ. Zurich, Zurich, Switz.
SOURCE: Helv. Chim. Acta (1966), 49(7), 2321-37
CODEN: HCACAV
DOCUMENT TYPE: Journal
LANGUAGE: German
GI For diagram(s), see printed CA Issue.
AB Structures I (R1 = OH, R2 = H, R3 = H2, R4 = O) (II) and I (R1 = H, R2 = OH, R3 = H2, R4 = O) (III) are proposed for fruticosine and fruticosamine, resp., on the basis of degradative, spectral, and synthetic evidence. Thus, a soln. of 100 mg. II in 2 ml. dry C5H5N was kept 2.5 days at 20.degree. with a mixt. of 100 mg. CrO3 and 3 ml. C5H5N to give 80 mg. oxofruticosine (I, R1 = OH, R2 = H, R3 = R4 = O) (IV), m. 215-18.degree. (decompn.) (MeOH-Et2O), shown to contain a 5-membered cyclic lactam by its ir spectrum. II and III were not oxidized by CrO3-AcOH. II (134 mg.) was mixed with 4 ml. Me2SO and 2.6 ml. Ac2O and kept 40 hrs. at 20.degree. to give 100 mg. diketone (V), m. 203-5.degree. after sublimation at 130-50.degree./0.0001 mm. A mixt. of 22 mg. V, 10 ml. aq. MeOH, and excess NaBH4 kept 1 hr. at 20.degree. gave 3 mg. III, 17 mg. II, and .apprx.5% dihydrofruitcosamine (I, R1 = OH, R2 = H, R3 = H2, R4 = H,OH) (VI), m. 245.degree. (decompn.). VI was also prepd. by redn. of III with NaBH4-CaCl2. A soln. of 119 mg. V in 30 ml. abs. MeOH was satd. with dry HCl and refluxed 1 hr. to give 82% chanofruitcosine methyl ester (VII), which gave an indefinite m.p. It was distd. at 160.degree./0.001 mm.; [.alpha.] 25 D 98.3.degree. (c 0.871, CHCl3). VII was also prepd. by treatment of III with Me2SO-Ac2O. A soln. of 22 mg. VII in 10 ml. 90% MeOH-H2O kept 1 hr. at 20.degree. with excess NaBH4 gave 15.3 mg. VIII, m.

225-7.degree., 238.degree. (Me2CO-Et2O-hexane), and 3 mg. IX, m. 175-9.degree. (Et2O). IX was converted in 95% yield to VIII upon heating 0.5 hr. at 160.degree. in vacuo. A mixt. of 50 mg. VII, 2 g. Zn dust, and 10 ml. 9:1 MeOH-concd. H2SO4 refluxed 3 hrs. gave 49 mg. dihydroisokopsine (X), m. 173.degree. (Et2O) (CA 59, 684a). A soln. of 20 mg. X in 10 ml. tetrahydrofuran was refluxed 1 hr. with excess LiAlH4 to give 9 mg. N-methyldecarbomethoxydihydroisokopsine, m. 158-60.degree. (Et2O-hexane). For the synthesis of II, kopsine was converted to isokopsine (XI) according to the method of Govindachari, et al. (loc. cit.). A soln. of 54 mg. XI in 10 ml. 2N H2SO4 was mixed with 45 mg. KIO4, kept 2 hrs. at 20.degree., and the crude product (45 mg.) esterified with HCl-MeOH to give 22 mg. VII. A soln. of 92 mg. X in 10 ml. abs. C5H5N was treated with a soln. of 200 mg. Pb(OAc)4 in 15 ml. C5H5N and kept 25 hrs. at 20.degree. to give 67 mg. XII, m. 196-202.degree.. XII was converted to II in 86-90% yield by treatment with NaOMe-MeOH at 20.degree. or with 2N HCl at 100.degree. in a sealed tube. Ir, uv, N.M.R., and mass spectra are tabulated or presented graphically for all compds. described, and the N.M.R. and mass spectra are discussed in detail. 20 references.

IT **14051-16-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 14051-16-2 CAPLUS

CN 6aH,10H-6b,9-Ethano-9,13,14b-metheno-5H-6,7-dioxa-4b,13-diazacyclonona[c]cyclopenta[lm]fluoren-5-one, 7a,8,11,12,14,14a-hexahydro-, stereoisomer (8CI) (CA INDEX NAME)



=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	102.18	775.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-14.11	-14.70

FILE 'REGISTRY' ENTERED AT 07:54:58 ON 17 DEC 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

Examiner Anderson 703-605-1157

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 16 DEC 2001 HIGHEST RN 375793-75-2
DICTIONARY FILE UPDATES: 16 DEC 2001 HIGHEST RN 375793-75-2

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d l7
L7 HAS NO ANSWERS
L7 STR



Structure attributes must be viewed using STN Express query preparation.

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.27	781.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-14.70

STN INTERNATIONAL LOGOFF AT 08:05:00 ON 17 DEC 2001